AdvanCell is radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 23, 2022 | Series B | $18M | 1 | Morningside Venture Investments | — | Detail |
Dec 23, 2021 | Grant | $2.10M | 1 | NSW Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Morningside Venture Investments | Yes | Series B |
NSW Health | Yes | Grant |